News headlines about Pediapharm (NASDAQ:PDP) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pediapharm earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.1210714644191 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Pediapharm (PDP) opened at $51.62 on Monday. Pediapharm has a 1 year low of $41.43 and a 1 year high of $51.72.

In other news, Director Benoit Gravel acquired 146,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The stock was acquired at an average price of $0.30 per share, for a total transaction of $43,800.00.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at

Pediapharm Company Profile

PowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index.

Receive News & Ratings for Pediapharm Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediapharm Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.